Background and Purpose—The safety and efficacy of restarting anticoagulation therapy after
intracranial hemorrhage (ICH) remain unclear. We performed a systematic review and meta …

Purpose of review Decision-making on resuming oral anticoagulant (OAC) after
intracerebral hemorrhage (ICH) evokes significant debate among clinicians. Such patients …

Resuming anticoagulation therapy after a potentially life-threatening bleeding complication
evokes high anxiety levels among clinicians and patients trying to decide whether resuming …

Importance Although use of oral anticoagulants (OACs) is increasing, there is a substantial
lack of data on how to treat OAC-associated intracerebral hemorrhage (ICH). Objective To …

Background While warfarin-related intracranial hemorrhage (ICH) occurs in 0.25%-1.1%
patients per year, little is known about the practice and outcomes of anticoagulant …

Objective Oral anticoagulation treatment (OAT) resumption is a therapeutic dilemma in
intracerebral hemorrhage (ICH) care, particularly for lobar hemorrhages related to amyloid …

Background and Purpose—The optimum timing of resumption of anticoagulation after
warfarin-related intracranial hemorrhage in patients with indication for continued …

Intracerebral hemorrhage (ICH) is the most feared and the most deadly complication of oral
anticoagulant therapy, eg, with warfarin (Coumadin). After such an event, clinicians wonder …

Background and Purpose—Warfarin increases both the likelihood and the mortality of
intracerebral hemorrhage (ICH), particularly in patients with a history of prior ICH. In light of …

Background and Purpose—Whether intracerebral hemorrhage (ICH) survivors should restart
antithrombotic drugs is unknown. We analyzed the frequency of restarting antithrombotic …